000			01700 a2200481 4500
005			20250515011339.0
264		0	_c20060717
008			200607s 0 0 eng d
022			_a0003-4967
024	7		_a10.1136/ard.2005.043638 _2doi
040			_aNLM _beng _cNLM
100	1		_aRaza, K
245	0	0	_aInfliximab leads to a rapid but transient improvement in endothelial function in patients with primary systemic vasculitis. _h[electronic resource]
260			_bAnnals of the rheumatic diseases _cJul 2006
300			_a946-8 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntirheumatic Agents _xtherapeutic use
650	0	4	_aArteritis _xdrug therapy
650	0	4	_aCyclophosphamide _xtherapeutic use
650	0	4	_aEndothelium, Vascular _xdrug effects
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aImmunosuppressive Agents _xtherapeutic use
650	0	4	_aInfliximab
650	0	4	_aLaser-Doppler Flowmetry
650	0	4	_aMale
650	0	4	_aMethylprednisolone _xtherapeutic use
650	0	4	_aMiddle Aged
650	0	4	_aPilot Projects
650	0	4	_aStatistics, Nonparametric
650	0	4	_aTime Factors
650	0	4	_aTumor Necrosis Factor-alpha _xantagonists & inhibitors
700	1		_aCarruthers, D M
700	1		_aStevens, R
700	1		_aFiler, A D
700	1		_aTownend, J N
700	1		_aBacon, P A
773	0		_tAnnals of the rheumatic diseases _gvol. 65 _gno. 7 _gp. 946-8
856	4	0	_uhttps://doi.org/10.1136/ard.2005.043638 _zAvailable from publisher's website
999			_c15981284 _d15981284